Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final Analysis of 3 Versus 6 Months of Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy in Patients With Stage III Colon Cancer: The Randomized Phase III ACHIEVE Trial.
Yoshino T, Oki E, Misumi T, Kotaka M, Manaka D, Eto T, Hasegawa J, Takagane A, Nakamura M, Kato T, Munemoto Y, Nakamura F, Bando H, Taniguchi H, Sakamoto Y, Shiozawa M, Nishi M, Horiuchi T, Yamagishi H, Sakamoto J, Mizushima T, Ohtsu A, Mori M. Yoshino T, et al. Among authors: munemoto y. J Clin Oncol. 2022 Oct 10;40(29):3419-3429. doi: 10.1200/JCO.21.02628. Epub 2022 May 5. J Clin Oncol. 2022. PMID: 35512259 Clinical Trial.
Multicenter study of short- and long-term outcomes of laparoscopic palliative resection for incurable, symptomatic stage IV colorectal cancer in Japan.
Akagi T, Inomata M, Kitano S, Hida K, Sakai Y, Hasegawa S, Kinjo Y, Yoshimura K, Ito M, Fukunaga Y, Kanazawa A, Idani H, Watanabe M; Japan Society of Laparoscopic Colorectal Surgery. Akagi T, et al. J Gastrointest Surg. 2013 Apr;17(4):776-83. doi: 10.1007/s11605-013-2173-x. Epub 2013 Feb 22. J Gastrointest Surg. 2013. PMID: 23435696
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H. Kono T, et al. Among authors: munemoto y. Cancer Chemother Pharmacol. 2013 Dec;72(6):1283-90. doi: 10.1007/s00280-013-2306-7. Cancer Chemother Pharmacol. 2013. PMID: 24121454 Free PMC article. Clinical Trial.
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. Iwamoto S, et al. Among authors: munemoto y. Ann Oncol. 2015 Jul;26(7):1427-33. doi: 10.1093/annonc/mdv197. Epub 2015 Apr 23. Ann Oncol. 2015. PMID: 25908603 Free PMC article. Clinical Trial.
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
Matsuda C, Munemoto Y, Mishima H, Nagata N, Oshiro M, Kataoka M, Sakamoto J, Aoyama T, Morita S, Kono T. Matsuda C, et al. Among authors: munemoto y. Cancer Chemother Pharmacol. 2015 Jul;76(1):97-103. doi: 10.1007/s00280-015-2767-y. Epub 2015 May 17. Cancer Chemother Pharmacol. 2015. PMID: 25983022 Free PMC article. Clinical Trial.
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Matsuda C, Honda M, Tanaka C, Fukunaga M, Ishibashi K, Munemoto Y, Hata T, Bando H, Oshiro M, Kobayashi M, Tokunaga Y, Fujii A, Nagata N, Oba K, Mishima H. Matsuda C, et al. Among authors: munemoto y. Int J Clin Oncol. 2016 Jun;21(3):566-72. doi: 10.1007/s10147-015-0911-7. Epub 2015 Oct 16. Int J Clin Oncol. 2016. PMID: 26475356 Clinical Trial.
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, Fukunaga M, Takagane A, Otsuji T, Miyake Y, Nagase M, Sakamoto J, Matsuoka M, Oba K, Mishima H. Munemoto Y, et al. BMC Cancer. 2015 Oct 24;15:786. doi: 10.1186/s12885-015-1712-0. BMC Cancer. 2015. PMID: 26497654 Free PMC article. Clinical Trial.
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E, Murata A, Yoshida K, Maeda K, Ikejiri K, Munemoto Y, Sasaki K, Matsuda C, Kotake M, Suenaga T, Matsuda H, Emi Y, Kakeji Y, Baba H, Hamada C, Saji S, Maehara Y. Oki E, et al. Among authors: munemoto y. Ann Oncol. 2016 Jul;27(7):1266-72. doi: 10.1093/annonc/mdw162. Epub 2016 Apr 7. Ann Oncol. 2016. PMID: 27056996 Free PMC article. Clinical Trial.
69 results